Saudi Arabia SFDA registration ME0000001000SFDAA00188
Anti-CD22 (SP104) Rabbit Monoclonal Primary Antibody
Product information
Reagent directed against the type 1 integral membrane glycoprotein
Product use
Anti-CD22 (SP104) Rabbit
Monoclonal Primary Antibody (anti-
CD22 (SP104)) is directed against the
type 1 integral membrane
glycoprotein, CD22. Anti-CD22
(SP104) exhibits a cell membranous
and/or cytoplasmic staining pattern
and may be used to aid in the
identification of B-cell lymphomas.
This antibody is intended for
qualitative staining of sections of
formalin-fixed, paraffin-embedded
tissue. This product should be interpreted by a qualified pathologist in conjunction with
histological examination, relevant clinical information and proper controls.
Device classification
- Risk Class
- General IVD(Others)
- Product Category
- Chemicals
- Product Type
- IVD
Registration information
- Registration ID
- ME0000001000SFDAA00188
- Authorization ID
- GHTF-2019-0925
- Status
- Active
- Expire Date
- May 27, 2024
Manufacturer
- Manufacturer Name
- Ventana Medical Systems, Inc.
Model information
- Model ID(s)
- 790-4588
Product accessories
[]
About this record
Access comprehensive regulatory information for Anti-CD22 (SP104) Rabbit Monoclonal Primary Antibody in the Saudi Arabia medical device market through Pure Global AI's free database. This General IVD(Others) device is registered with Saudi Arabia SFDA under registration number ME0000001000SFDAA00188 and manufactured by Ventana Medical Systems, Inc..
This page provides complete registration details including product category (Chemicals), manufacturer information, model details, and regulatory compliance data from the official Saudi Arabia SFDA medical device database. Pure Global AI offers free access to Saudi Arabia's complete medical device registry, helping global MedTech companies navigate SFDA regulations efficiently.
Free DatabasePowered by Pure Global AISFDA Official DataGeneral IVD(Others)